Previous Close | 0.42 |
1-Year Change | -46.97% |
6-Months Change | -82.2% |
3-Months Change | -61.82% |
Moving Avg (50d) | 0.6181 |
Moving Avg (200d) | 1.1606 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 42.2M |
Beta (3-Years) | 1.45 |
Revenue Growth (ttm) | 33.11% |
Net Profit Margin (ttm) | -96.84% |
Return On Assets (ttm) | -57.41% |
EPS (ttm) | -1.71 |
PE Ratio (ttm) | -0.25 |
Dividend Yield | % |
Asset Description: | FibroGen, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-13 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
0.412 | 0.399 | 0.391 | 0.378 | 0.357 | 0.336 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |